白消安联合环磷酰胺对比全身照射联合环磷酰胺用于成人急性B淋巴细胞白血病:一项开放标签、多中心、III期试验
这项在中国13家医院开展的开放标签随机III期试验,将275例接受HLA匹配异基因造血干细胞移植的成人标危B细胞急性淋巴细胞白血病首次完全缓解患者按1:1随机分配至BuCy组或TBI-Cy组。BuCy组2年总生存率为76.6%,TBI-Cy组为79.4%,达到非劣效;两组2年复发率、非复发死亡率及毒性无差异。
要点
- BuCy方案在成人标危B-ALL首次完全缓解患者中,2年总生存非劣效于TBI-Cy方案。
- BuCy组与TBI-Cy组的2年总生存率分别为76.6%与79.4%,差异无统计学显著。
- 两组在方案相关毒性、移植物抗宿主病及晚期效应方面无差异。
核心结论
- 对于接受HLA匹配异基因造血干细胞移植的成人标危B细胞急性淋巴细胞白血病首次完全缓解患者,BuCy方案的有效性和安全性非劣效于TBI-Cy(4.5 Gy×2)方案。
研究设计与样本
- 开放标签、随机、多中心III期试验,在中国13家医院开展,纳入年龄14-65岁的标危急性淋巴细胞白血病首次完全缓解患者。
- 患者按1:1随机分配至BuCy组(白消安0.8 mg/kg每日四次,第-7至-4天;环磷酰胺60 mg/kg每日一次,第-3至-2天)或TBI-Cy组(第-5至-4天行4.5 Gy全身照射;环磷酰胺60 mg/kg每日一次,第-3至-2天)。
- 主要终点为2年总生存率,采用符合方案集分析;2016年1月至2020年2月期间,BuCy组分配275例(评估273例),TBI-Cy组分配275例(评估272例)。
主要发现
- BuCy组2年总生存率为76.6%(95%CI 71.7-81.8),TBI-Cy组为79.4%(95%CI 74.7-84.4;P=.457;差异2.9%,95%CI -4.1至9.8;P=.022),表明BuCy非劣效。
- BuCy组2年复发率为20.2%(95%CI 15.6-25.1),TBI-Cy组为18.4%(95%CI 14.0-23.2;P=.616)。
- BuCy组非复发死亡率为11.0%(95%CI 7.6-15.0),TBI-Cy组为11.0%(95%CI 7.7-15.1;P=.988)。
- 两组在方案相关毒性、移植物抗宿主病或晚期效应方面无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It remains controversial whether busulfan-based versus total body irradiation (TBI)-based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). We investigated the efficacy and toxicity of busulfan plus cyclophosphamide (BuCy) and TBI plus cyclophosphamide (TBI-Cy) conditioning in allo-HSCT for adult standard-risk B-cell-ALL in first complete remission (CR1). PATIENTS AND METHODS: We performed an open-label, randomized phase III trial at 13 hospitals in China. Eligible patients (age 14-65 years) had standard-risk ALL in CR1. Patients were randomly assigned (1:1) to BuCy (0.8 mg/kg four times per day on days -7 to -4 and cyclophosphamide 60 mg/kg once daily on days -3 to -2) or TBI-Cy (4.5 Gy TBI on days -5 to -4 and cyclophosphamide 60 mg/kg once daily on days -3 to -2). The primary end point was 2-year overall survival. Analysis was per protocol. This trial is registered with ClinicalTrials.gov (identifier: NCT02670252) and is complete. RESULTS: Between January 2016 and February 2020, 275 patients were assigned to receive BuCy (273 assessed) and 275 to TBI-Cy (272 assessed). The 2-year overall survival was 76.6% (95% CI, 71.7 to 81.8) and 79.4% (74.7 to 84.4; P = .457; difference 2.9%; 95% CI, -4.1 to 9.8; P = .022), indicating noninferiority of BuCy. The 2-year relapse was 20.2% (95% CI, 15.6 to 25.1) and 18.4% (14.0 to 23.2; P = .616), and the nonrelapse mortality was 11.0% (95% CI, 7.6 to 15.0) and 11.0% (7.7 to 15.1; P = .988) in the BuCy and TBI-Cy groups, respectively. There were no differences in regimen-related toxicity, graft-versus-host disease, or late effects between the two groups. CONCLUSION: The BuCy regimen has noninferior efficiency and safety as TBI-Cy (4.5 Gy × 2) for patients with adult standard-risk B cell-ALL in CR1 undergoing HLA-matched allo-HSCT.
引用
- Zhang H, Fan Z, Huang F, et al. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol. 2022. PMID: 36084276. doi:10.1200/JCO.22.00767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。